pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 10·1 min read
save

Pfizer promotes Danna Breen to lead obesity discovery, succeeding Kendra Bence

Jul 10, 2026·read at Endpoints ↗Neutral

Pfizer announced that Danna Breen has been promoted to head of its obesity discovery program, according to a LinkedIn post.

Breen takes over from Kendra Bence and brings nearly 14 years of experience within Pfizer to the role.

The news was released alongside a brief note that AI startup Xaira is also undergoing leadership adjustments, though no further details were provided.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Pfizer appoints obesity discovery head; AI startup Xaira makes leadership adjustments”

read at Endpoints ↗
91 words · retrieved Jul 10
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
PFIZER4
drugs
Obesity3
topics
Obesity3

related stories

  • Jun 8STAT+: Novo underwhelmed by drug it once fought Pfizer forSTAT
  • Jun 8Major readouts from the annual diabetes conferenceSTAT
  • Jun 8STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rateSTAT
  • Jun 8Opinion: $2 million gene therapy cures require a financing modelSTAT
  • Jun 7STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drugSTAT